BioCentury | Apr 8, 2021
Emerging Company Profile

Crossovers Fidelity, Surveyor invest early in ValenzaBio, backing $70M series A for rare autoimmune play

With a $70 million series A round led by Fidelity in a syndicate that included crossover Surveyor, start-up ValenzaBio is readying to take antibodies licensed from CRUK and Pierre Fabre into early clinical...
BioCentury | Jan 1, 2021

Another year of firsts in FDA’s new drug approvals

The COVID-19 pandemic didn’t stand in the way of new drug approvals by FDA in 2020, but few new modalities crossed the finish line despite the clinical development fervor around platform technologies and...
BioCentury | Dec 18, 2020
Product Development

Realities of limited manufacturing capacity for COVID-19 vaccines hit Horizon’s Tepezza launch

In a blow to what has been one of the more successful drug launches of the year, Operation Warp Speed has commandeered some of Horizon’s manufacturing slots for thyroid eye disease drug Tepezza to prioritize a COVID-19 vaccine. The...
BioCentury | Nov 24, 2020
Product Development

Nov. 23 Quick Takes: NIH panel says bamlanivimab should not be considered COVID-19 SOC; plus Eiger, Shionogi-Roche, Kiniksa, Schrödinger, Halozyme-Horizon and Immunicum-DCPrime

NIH panel says bamlanivimab should not be considered standard-of-care for COVID-19NIH’s COVID-19 Treatment Guidelines Panel said there is not enough data to recommend either for or against use of bamlanivimab from Eli Lilly and Co. (NYSE:LLY)...
BioCentury | Oct 30, 2020

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

Ultragenyx, Scholar Rock offerings Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Scholar Rock Holding Corp. (NASDAQ:SRRK) raised follow-ons late Wednesday. Ultragenyx raised $400 million, while Scholar Rock raised $200 million via the shares and prefunded warrants after its stock more...
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

RayzeBio thinks its targeting and radioisotope strategies can take radiopharmaceuticals from  a series of individual success stories to a broadly applicable platform technology for cancer. The company...
BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

Horizon raising cash after Tepezza beats sales estimate Shares of Horizon Therapeutics plc (NASDAQ:HZNP) rose 24% Wednesday, adding nearly $2.9 billion to the company’s market cap after a 2Q20 earnings report that showed that sales...
BioCentury | Jul 29, 2020

Enthera’s €28M series A latest sign of growth for Italy’s biotech ecosystem

U.S. and European investors are backing the largest-ever series A financing for an Italian biotech, autoimmune play Enthera s.r.l. Enthera raised €28 million ($32.8 million) in the round, which was led by existing investor Sofinnova...
BioCentury | Jul 18, 2020

Spark vet Furey steering Imvax into glioblastoma Phase II with $112M series C

A $112 million series C round will help Imvax move its autologous neoantigen immunotherapy into Phase II testing for glioblastoma. The therapy, which CEO John Furey told BioCentury is first in class, uses a patient’s...
BioCentury | Jun 27, 2020

Boxed warning on Zogenix’s Dravet syndrome therapy could hamper market prospects

FDA’s approval of a resubmitted NDA for Fintepla to treat seizures associated with Dravet syndrome sets Zogenix up to compete with GW’s Epidiolex in the rare epilepsy market, but the drug’s prospects may be hampered...
Items per page:
1 - 10 of 824